Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.73 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 5/20 | 0.47 |
| ▸ | MYC | P01106 | 3/20 | 0.46 |
| ▸ | ERN1 | O75460 | 2/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27605185 | 0.86 | KEAP1 (0.77) | KEAP1HDAC2KAT6AERN1PRMT6 | |
| SCHEMBL941410 | 0.84 | KEAP1 (1.00) | KEAP1HDAC2KAT6A | |
| SCHEMBL17777307 | 0.83 | KEAP1 (0.73) | KEAP1HDAC2KAT6AERN1PRMT6 | |
| SCHEMBL4964453 | 0.80 | TAAR1 (0.57) | KEAP1HDAC2PARP1MYCERN1 | |
| SCHEMBL28990328 | 0.80 | KEAP1 (0.69) | KEAP1HDAC2KAT6AERN1PRMT6 | |
| SCHEMBL16810390 | 0.79 | MYC (0.73) | KEAP1MYC | |
| SCHEMBL2431097 | 0.79 | PARP1 (0.64) | PARP1ERN1 | |
| SCHEMBL31422694 | 0.79 | PARP1 (0.64) | PARP1ERN1 | |
| SCHEMBL17773161 | 0.79 | KEAP1 (0.67) | KEAP1HDAC2KAT6AERN1PRMT6 | |
| SCHEMBL18311308 | 0.79 | KAT6A (0.55) | KEAP1HDAC2KAT6APARP1MYC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2131656-A2 | PHTHALAZINE DERIVATIVES | Forest Laboratories Holdings Limited (BM) | 2009-12-16 | — | — | EP | claimed |
| US-20080146547-A1 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-06-19 | — | — | US | claimed |
| WO-2008061108-A2 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-05-22 | — | — | WO | claimed |
| US-8349836-B2 | Phthalazine derivatives as inhibitors of protein kinase | ARALDI GIAN-LUCA (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2131656-A2 | PHTHALAZINE DERIVATIVES | Forest Laboratories Holdings Limited (BM) | 2009-12-16 | — | — | EP | disclosed |
| US-20080146547-A1 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-06-19 | — | — | US | disclosed |
| WO-2008061108-A2 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146547-A1 | PHTHALAZINE DERIVATIVES | CDK5, HIPK2, PACSIN2 | KEAP1 170/4885HDAC2 106/4885KAT6A 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.